17 results on '"Cedraro N"'
Search Results
2. Inhibition of polymorphic MexXY-OprM efflux system in Pseudomonas aeruginosa clinical isolates by Berberine derivatives.
- Author
-
Giorgini G, Di Gregorio A, Mangiaterra G, Cedraro N, Minnelli C, Sabbatini G, Mobbili G, Simoni S, Vignaroli C, and Galeazzi R
- Subjects
- Biological Transport, Anti-Bacterial Agents pharmacology, Allosteric Site, Pseudomonas aeruginosa, Berberine pharmacology
- Abstract
The MexXY-OprM multidrug efflux pump (EP) in aminoglycosides resistant Pseudomonas aeruginosa is one of the major resistance mechanisms, which is often overexpressed in strains isolated from pulmonary chronic disease such as cystic fibrosis.
[1-3] In this research, we focused on the design of potential efflux pumps inhibitors, targeting MexY, the inner membrane component, in an allosteric site. Berberine[4] has been considered as lead molecule since we previously demonstrated its effectiveness in targeting MexY in laboratory reference strains.[5,6] Since this protein is often present in polymorphic variants in clinical strains, we sequenced and modeled all the mutated forms and we synthesized and evaluated by computational techniques, some berberine derivatives carrying an aromatic functionalization in its 13-C ring position. These compounds were tested in vitro against clinical P. aeruginosa strains for antimicrobial and antibiofilm activity. In conclusion, the results demonstrated the importance of the aromatic moiety functionalization in exerting the EP inhibitory activity in synergy with the aminoglycoside tobramycin. More, we found that aminoacidic composition of MexY in different strains must be considered for predicting potential binding site and affects the different activity of berberine derivatives. Finally, the antibiofilm effect of these new EPIs is promising, particularly for o-CH3-berberine derivative., (© 2024 Wiley-VCH GmbH.)- Published
- 2024
- Full Text
- View/download PDF
3. Role of viable but non culturable cells in patients with cystic fibrosis in the era of highly effective modulator therapy.
- Author
-
Cirilli N, Schiavoni V, Tagliabracci V, Gesuita R, Tiano L, Fabrizzi B, D'Antuono A, Peruzzi A, Cedraro N, Carle F, Moretti M, Ferrante L, Vignaroli C, Biavasco F, and Mangiaterra G
- Abstract
Background: Lung infections antibiotic treatment in Cystic Fibrosis patients (pwCF) is often complicated by bacterial persisters, including the so-called Viable but Non Culturable (VBNC) forms, live cells undetected by the routine cultural microbiological methods. This study investigated the occurrence of VBNC cells of five CF bacterial pathogens in 94 pwCF over one year and the possible associations with the patients' clinical features., Methods: Sputum samples, recovered at routine visits and during exacerbation episodes, were analyzed for the presence of the five pathogens by both routine culture-based assays and species-specific qPCR. VBNC cells were estimated as the difference between molecular and cultural counts and their presence was matched with the clinical data in particular the therapeutic regimens., Results: All but ten pwCF showed the presence of VBNC cells at least once during the study. Pseudomonas aeruginosa and methicillin-susceptible Staphylococcus aureus were the species most frequently found in the VBNC state. Only the former showed a significant association between chronic infection and VBNC cells presence; VBNC-MSSA positive patients significantly increased overtime. The presence of non culturable bacteria was generally concurrent with poor lung functionality and more frequent pulmonary exacerbations. No significant association with modulator treatment was evidenced., Conclusions: The obtained data demonstrated the overwhelming occurrence of bacterial VBNC cells in CF lung infections, warranting a constant monitoring of pwCF and underlining the need of implementing the routine culture-based assays with culture-independent techniques. This is pivotal to understand the CF bacterial population dynamics and to efficiently contrast the lung infection progression and worsening., Competing Interests: Declaration of competing interest The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Involvement of Acquired Tobramycin Resistance in the Shift to the Viable but Non-Culturable State in Pseudomonas aeruginosa .
- Author
-
Mangiaterra G, Cedraro N, Vaiasicca S, Citterio B, Frangipani E, Biavasco F, and Vignaroli C
- Subjects
- Humans, Tobramycin pharmacology, Pseudomonas aeruginosa, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Aminoglycosides pharmacology, Microbial Sensitivity Tests, Pseudomonas Infections microbiology, Cystic Fibrosis drug therapy
- Abstract
Persistent and viable but non-culturable (VBNC) Pseudomonas aeruginosa cells are mainly responsible for the recurrence and non-responsiveness to antibiotics of cystic fibrosis (CF) lung infections. The sub-inhibitory antibiotic concentrations found in the CF lung in between successive therapeutic cycles can trigger the entry into the VBNC state, albeit with a strain-specific pattern. Here, we analyzed the VBNC cell induction in the biofilms of two CF P. aeruginosa isolates, exposed to starvation with/without antibiotics, and investigated the putative genetic determinants involved. Total viable bacterial cells were quantified by the validated ecfX -targeting qPCR protocol and the VBNC cells were estimated as the difference between qPCR and cultural counts. The isolates were both subjected to whole genome sequencing, with attention focused on their carriage of aminoglycoside resistance genes and on identifying mutated toxin-antitoxin and quorum sensing systems. The obtained results suggest the variable contribution of different antibiotic resistance mechanisms to VBNC cell abundance, identifying a major contribution from tobramycin efflux, mediated by MexXY efflux pump overexpression. The genome analysis evidenced putative mutation hotspots, which deserve further investigation. Therefore, drug efflux could represent a crucial mechanism through which the VBNC state is entered and a potential target for anti-persistence strategies., Competing Interests: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2023
- Full Text
- View/download PDF
5. New C-6 functionalized quinoline NorA inhibitors strongly synergize with ciprofloxacin against planktonic and biofilm growing resistant Staphylococcus aureus strains.
- Author
-
Felicetti T, Cedraro N, Astolfi A, Cernicchi G, Mangiaterra G, Vaiasicca S, Massari S, Manfroni G, Barreca ML, Tabarrini O, Biavasco F, Cecchetti V, Vignaroli C, and Sabatini S
- Subjects
- Anti-Bacterial Agents chemistry, Anti-Bacterial Agents pharmacology, Bacterial Proteins, Biofilms, Ciprofloxacin pharmacology, Humans, Microbial Sensitivity Tests, Multidrug Resistance-Associated Proteins, Plankton metabolism, Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus metabolism, Staphylococcal Infections
- Abstract
Antimicrobial resistance (AMR) represents a global health issue threatening our social lifestyle and the world economy. Efflux pumps are widely involved in AMR by playing a primary role in the development of specific mechanisms of resistance. In addition, they seem to be involved in the process of biofilm formation and maintenance, contributing to enhance the risk of creating superbugs difficult to treat. Accordingly, the identification of non-antibiotic molecules able to block efflux pumps, namely efflux pump inhibitors (EPIs), could be a promising strategy to counteract AMR and restore the antimicrobial activity of ineffective antibiotics. Herein, we enlarge the knowledge about the structure-activity relationship of 2-phenylquinoline Staphylococcus aureus NorA EPIs by reporting a new series of very potent C-6 functionalized derivatives. Best compounds significantly inhibited ethidium bromide efflux in a NorA-overexpressing S. aureus strain (SA-1199B) and strongly synergized at very low concentrations (0.20-0.78 μg/mL) with ciprofloxacin (CPX) against CPX-resistant S. aureus strains (SA-1199B and SA-K2378), as proved by checkerboard and time-kill experiments. In addition, some of these EPIs (9b and 10a) produced a post-antibiotic effect of 1.2 h and strongly enhanced antibiofilm activity of CPX against SA-1199B strain. Interestingly, at the concentrations used to reach synergy with CPX against resistant S. aureus strains, most of the EPI compounds did not show any human cell toxicity. Finally, by exploiting the recent released crystal structure of NorA, we observed that best EPI 9b highlighted a favourable docking pose, establishing some interesting interactions with key residues., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
6. Zooplankton as a Transitional Host for Escherichia coli in Freshwater.
- Author
-
Di Cesare A, Riva F, Colinas N, Borgomaneiro G, Borin S, Cabello-Yeves PJ, Canale C, Cedraro N, Citterio B, Crotti E, Mangiaterra G, Mapelli F, Mondino V, Vignaroli C, Quaranta W, Corno G, Fontaneto D, and Eckert EM
- Subjects
- Animals, Bacteria, Daphnia microbiology, Feces microbiology, Fresh Water microbiology, Zooplankton microbiology, Drinking Water, Escherichia coli genetics
- Abstract
This study shows that Escherichia coli can be temporarily enriched in zooplankton under natural conditions and that these bacteria can belong to different phylogroups and sequence types (STs), including environmental, clinical, and animal isolates. We isolated 10 E. coli strains and sequenced the genomes of two of them. Phylogenetically, the two isolates were closer to strains isolated from poultry meat than to freshwater E. coli, albeit their genomes were smaller than those of the poultry isolates. After isolation and fluorescent protein tagging of strains ED1 and ED157, we show that Daphnia sp. can take up these strains and release them alive again, thus becoming a temporary host for E. coli. In a chemostat experiment, we show that this association does not prolong bacterial long-term survival, but at low abundances it also does not significantly reduce bacterial numbers. We demonstrate that E. coli does not belong to the core microbiota of Daphnia , suffers from competition by the natural Daphnia microbiota, but can profit from its carapax to survive in water. All in all, this study suggests that the association of E. coli with Daphnia is only temporary, but the cells are viable therein, and this might allow encounters with other bacteria for genetic exchange and potential genomic adaptation to the freshwater environment. IMPORTANCE The contamination of freshwater with feces-derived bacteria is a major concern regarding drinking water acquisition and recreational activities. Ecological interactions promoting their persistence are still very scarcely studied. This study, which analyses the survival of E. coli in the presence of zooplankton, is thus of ecological and water safety relevance.
- Published
- 2022
- Full Text
- View/download PDF
7. Berberine Derivatives as Pseudomonas aeruginosa MexXY-OprM Inhibitors: Activity and In Silico Insights.
- Author
-
Giorgini G, Mangiaterra G, Cedraro N, Laudadio E, Sabbatini G, Cantarini M, Minnelli C, Mobbili G, Frangipani E, Biavasco F, and Galeazzi R
- Subjects
- Amino Acid Sequence, Bacterial Proteins genetics, Berberine analogs & derivatives, Binding Sites, Chemistry Techniques, Synthetic, Drug Synergism, Microbial Sensitivity Tests, Molecular Docking Simulation, Molecular Dynamics Simulation, Molecular Structure, Polymorphism, Genetic, Protein Binding, Pseudomonas aeruginosa genetics, Structure-Activity Relationship, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents pharmacology, Bacterial Proteins antagonists & inhibitors, Bacterial Proteins chemistry, Berberine chemistry, Berberine pharmacology, Pseudomonas aeruginosa drug effects
- Abstract
The natural alkaloid berberine has been demonstrated to inhibit the Pseudomonas aeruginosa multidrug efflux system MexXY-OprM, which is responsible for tobramycin extrusion by binding the inner membrane transporter MexY. To find a structure with improved inhibitory activity, we compared by molecular dynamics investigations the binding affinity of berberine and three aromatic substituents towards the three polymorphic sequences of MexY found in P. aeruginosa (PAO1, PA7, and PA14). The synergy of the combinations of berberine or berberine derivatives/tobramycin against the same strains was then evaluated by checkerboard and time-kill assays. The in silico analysis evidenced different binding modes depending on both the structure of the berberine derivative and the specific MexY polymorphism. In vitro assays showed an evident MIC reduction (32-fold and 16-fold, respectively) and a 2-3 log greater killing effect after 2 h of exposure to the combinations of 13-(2-methylbenzyl)- and 13-(4-methylbenzyl)-berberine with tobramycin against the tobramycin-resistant strain PA7, a milder synergy (a 4-fold MIC reduction) against PAO1 and PA14, and no synergy against the Δ mexXY strain K1525, confirming the MexY-specific binding and the computational results. These berberine derivatives could thus be considered new hit compounds to select more effective berberine substitutions and their common path of interaction with MexY as the starting point for the rational design of novel MexXY-OprM inhibitors.
- Published
- 2021
- Full Text
- View/download PDF
8. From Quinoline to Quinazoline-Based S. aureus NorA Efflux Pump Inhibitors by Coupling a Focused Scaffold Hopping Approach and a Pharmacophore Search.
- Author
-
Cedraro N, Cannalire R, Astolfi A, Mangiaterra G, Felicetti T, Vaiasicca S, Cernicchi G, Massari S, Manfroni G, Tabarrini O, Cecchetti V, Barreca ML, Biavasco F, and Sabatini S
- Subjects
- Anti-Bacterial Agents chemical synthesis, Anti-Bacterial Agents chemistry, Bacterial Proteins metabolism, Cell Line, Cell Survival drug effects, Dose-Response Relationship, Drug, Humans, Methicillin-Resistant Staphylococcus aureus metabolism, Microbial Sensitivity Tests, Molecular Structure, Multidrug Resistance-Associated Proteins metabolism, Quinazolines chemical synthesis, Quinazolines chemistry, Quinolines chemical synthesis, Quinolines chemistry, Structure-Activity Relationship, Anti-Bacterial Agents pharmacology, Bacterial Proteins antagonists & inhibitors, Methicillin-Resistant Staphylococcus aureus drug effects, Multidrug Resistance-Associated Proteins antagonists & inhibitors, Quinazolines pharmacology, Quinolines pharmacology
- Abstract
Antibiotic resistance breakers, such as efflux pump inhibitors (EPIs), represent a powerful alternative to the development of new antimicrobials. Recently, by using previously described EPIs, we developed pharmacophore models able to identify inhibitors of NorA, the most studied efflux pump of Staphylococcus aureus. Herein we report the pharmacophore-based virtual screening of a library of new potential NorA EPIs generated by an in-silico scaffold hopping approach of the quinoline core. After chemical synthesis and biological evaluation of the best virtual hits, we found the quinazoline core as the best performing scaffold. Accordingly, we designed and synthesized a series of functionalized 2-arylquinazolines, which were further evaluated as NorA EPIs. Four of them exhibited a strong synergism with ciprofloxacin and a good inhibition of ethidium bromide efflux on resistant S. aureus strains coupled with low cytotoxicity against human cell lines, thus highlighting a promising safety profile., (© 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH.)
- Published
- 2021
- Full Text
- View/download PDF
9. The Natural Alkaloid Berberine Can Reduce the Number of Pseudomonas aeruginosa Tolerant Cells.
- Author
-
Mangiaterra G, Cedraro N, Laudadio E, Minnelli C, Citterio B, Andreoni F, Mobbili G, Galeazzi R, and Biavasco F
- Subjects
- Amino Acid Sequence, Bacterial Proteins, Biofilms drug effects, Cystic Fibrosis microbiology, Drug Resistance, Bacterial, Humans, Microbial Sensitivity Tests, Molecular Docking Simulation, Protein Structure, Quaternary, Pseudomonas Infections drug therapy, Tobramycin pharmacology, Berberine pharmacology, Pseudomonas aeruginosa drug effects
- Abstract
The eradication of recurrent Pseudomonas aeruginosa (PA) lung infection in cystic fibrosis (CF) patients may be hampered by the development of persistent bacterial forms, which can tolerate antibiotics through efflux pump overexpression. After demonstrating the efflux pump inhibitory effect of the alkaloid berberine on the PA MexXY-OprM efflux pump, in this study, we tested its ability (80/320 μg/mL) to enhance tobramycin (20xMIC/1000xMIC) activity against PA planktonic/biofilm cultures. Preliminary investigations of the involvement of MexY in PA tolerance to tobramycin treatment, performed on the isogenic pair PA K767 (wild type)/K1525 (Δ mexY ) growing in planktonic and biofilm cultures, demonstrated that the Δ mexY mutant K1525 produced a lower (100 and 10 000 times, respectively) amount of tolerant cells than that of the wild type. Next, we grew broth cultures of PAO1, PA14, and 20 PA clinical isolates (of which 13 were from CF patients) in the presence of 20xMIC tobramycin with and without berberine 80 μg/mL. Accordingly, most strains showed a greater (from 10- to 1000-fold) tolerance reduction in the presence of berberine. These findings highlight the involvement of the MexXY-OprM system in the tobramycin tolerance of PA and suggest that berberine may be used in new valuable therapeutic combinations to counteract persister survival.
- Published
- 2021
- Full Text
- View/download PDF
10. Linezolid Resistance Genes in Enterococci Isolated from Sediment and Zooplankton in Two Italian Coastal Areas.
- Author
-
Fioriti S, Coccitto SN, Cedraro N, Simoni S, Morroni G, Brenciani A, Mangiaterra G, Vignaroli C, Vezzulli L, Biavasco F, and Giovanetti E
- Subjects
- Animals, Enterococcus drug effects, Enterococcus genetics, Environmental Monitoring, Genes, Bacterial, Italy, Anti-Bacterial Agents pharmacology, Drug Resistance, Bacterial genetics, Enterococcus isolation & purification, Geologic Sediments microbiology, Linezolid pharmacology, Zooplankton microbiology
- Abstract
Linezolid is a last-resort antibiotic for the treatment of severe infections caused by multidrug-resistant Gram-positive organisms; although linezolid resistance remains uncommon, the number of linezolid-resistant enterococci has increased in recent years due to worldwide spread of acquired resistance genes ( cfr , optrA , and poxtA ) in clinical, animal, and environmental settings. In this study, we investigated the occurrence of linezolid-resistant enterococci in marine samples from two coastal areas in Italy. Isolates grown on florfenicol-supplemented Slanetz-Bartley agar plates were investigated for their carriage of optrA , poxtA , and cfr genes; optrA was found in one Enterococcus faecalis isolate, poxtA was found in three Enterococcus faecium isolates and two Enterococcus hirae isolates, and cfr was not found. Two of the three poxtA -carrying E. faecium isolates and the two E. hirae isolates showed related pulsed-field gel electrophoresis (PFGE) profiles. Two E. faecium isolates belonged to the new sequence type 1710, which clustered in clonal complex 94, encompassing nosocomial strains. S1 PFGE/hybridization assays showed a double (chromosome and plasmid) location of poxtA and a plasmid location of optrA Whole-genome sequencing revealed that poxtA was contained in a Tn 6657 -like element carried by two plasmids (pEfm-EF3 and pEh-GE2) of similar size, found in different species, and that poxtA was flanked by two copies of IS 1216 in both plasmids. In mating experiments, all but one strain ( E. faecalis EN3) were able to transfer the poxtA gene to E. faecium 64/3. The occurrence of linezolid resistance genes in enterococci from marine samples is of great concern and highlights the need to improve practices aimed at limiting the transmission of linezolid-resistant strains to humans from environmental reservoirs. IMPORTANCE Linezolid is one of the few antimicrobials available to treat severe infections due to drug-resistant Gram-positive bacteria; therefore, the emergence of linezolid-resistant enterococci carrying transferable resistance determinants is of great concern for public health. Linezolid resistance genes ( cfr , optrA , and poxtA ), often plasmid located, can be transmitted via horizontal gene transfer and have the potential to spread globally. This study highlights the detection of enterococci carrying linezolid resistance genes from sediment and zooplankton samples from two coastal urban areas in Italy. The presence of clinically relevant resistant bacteria, such as linezolid-resistant enterococci, in marine environments could reflect their spillover from human and/or animal reservoirs and could indicate that coastal seawaters also might represent a source of these resistance genes., (Copyright © 2021 American Society for Microbiology.)
- Published
- 2021
- Full Text
- View/download PDF
11. Contribution of Drugs Interfering with Protein and Cell Wall Synthesis to the Persistence of Pseudomonas aeruginosa Biofilms: An In Vitro Model.
- Author
-
Mangiaterra G, Carotti E, Vaiasicca S, Cedraro N, Citterio B, La Teana A, and Biavasco F
- Subjects
- Azabicyclo Compounds pharmacology, Biofilms drug effects, Ceftazidime pharmacology, Cell Wall drug effects, Ciprofloxacin pharmacology, Cyclic GMP analogs & derivatives, Cyclic GMP metabolism, Drug Combinations, Drug Resistance, Multiple, Bacterial, Gene Expression Regulation, Bacterial drug effects, Green Fluorescent Proteins genetics, Green Fluorescent Proteins metabolism, In Vitro Techniques, Microbial Sensitivity Tests, Pseudomonas aeruginosa drug effects, Transformation, Bacterial, Anti-Bacterial Agents pharmacology, Bacterial Proteins metabolism, Biofilms growth & development, Pseudomonas aeruginosa physiology, Tobramycin pharmacology
- Abstract
The occurrence of Pseudomonas aeruginosa (PA) persisters, including viable but non-culturable (VBNC) forms, subpopulations of tolerant cells that can survive high antibiotic doses, is the main reason for PA lung infections failed eradication and recurrence in Cystic Fibrosis (CF) patients, subjected to life-long, cyclic antibiotic treatments. In this paper, we investigated the role of subinhibitory concentrations of different anti-pseudomonas antibiotics in the maintenance of persistent (including VBNC) PA cells in in vitro biofilms. Persisters were firstly selected by exposure to high doses of antibiotics and their abundance over time evaluated, using a combination of cultural, qPCR and flow cytometry assays. Two engineered GFP-producing PA strains were used. The obtained results demonstrated a major involvement of tobramycin and bacterial cell wall-targeting antibiotics in the resilience to starvation of VBNC forms, while the presence of ciprofloxacin and ceftazidime/avibactam lead to their complete loss. Moreover, a positive correlation between tobramycin exposure, biofilm production and c-di-GMP levels was observed. The presented data could allow a deeper understanding of bacterial population dynamics during the treatment of recurrent PA infections and provide a reliable evaluation of the real efficacy of the antibiotic treatments against the bacterial population within the CF lung.
- Published
- 2021
- Full Text
- View/download PDF
12. Diffusion and Characterization of Pseudomonas aeruginosa Aminoglycoside Resistance in an Italian Regional Cystic Fibrosis Centre.
- Author
-
Mangiaterra G, Cedraro N, Citterio B, Simoni S, Vignaroli C, and Biavasco F
- Subjects
- Aminoglycosides pharmacology, Anti-Bacterial Agents pharmacology, Bacterial Proteins, Humans, Italy, Microbial Sensitivity Tests, Cystic Fibrosis drug therapy, Cystic Fibrosis genetics, Pseudomonas aeruginosa genetics
- Abstract
Aims: Extensively-drug-resistant Pseudomonas aeruginosa constitutes a serious threat to patients suffering from Cystic Fibrosis (CF). In these patients, P. aeruginosa lung infection is commonly treated with aminoglycosides, but treatments are largely unsuccessful due a variety of resistance mechanisms. Here we investigate the prevalence of resistance to gentamicin, amikacin and tobramycin and the main aminoglycoside resistance genes found in P. aeruginosa strains isolated at a regional CF centre., Results: A total number of 147 randomly selected P. aeruginosa strains isolated from respiratory samples sent by the Marche regional Cystic Fibrosis Centre to the Microbiology lab, were included in this study. Of these, 78 (53%) were resistant to at least one of the three aminoglycosides tested and 27% were resistant to all three antibiotics, suggesting a major involvement of a chromosome-encoded mechanism, likely MexXY-OprM efflux pump overexpression. A specific pathogenic clone (found in 7/78 of the aminoglycoside resistant strains) carrying ant(2″)-Ia was isolated over time from the same patient, suggesting a role for this additional resistance gene in the antibiotic unresponsiveness of CF patients., Conclusions: The MexXY-OprM efflux pump is confirmed as the resistance determinant involved most frequently in P. aeruginosa aminoglycoside resistance of CF lung infections, followed by the ant(2″)-Ia-encoded adenylyltransferase. The latter may prove to be a novel target for new antimicrobial combinations against P. aeruginosa.
- Published
- 2021
- Full Text
- View/download PDF
13. C-2 phenyl replacements to obtain potent quinoline-based Staphylococcus aureus NorA inhibitors.
- Author
-
Felicetti T, Mangiaterra G, Cannalire R, Cedraro N, Pietrella D, Astolfi A, Massari S, Tabarrini O, Manfroni G, Barreca ML, Cecchetti V, Biavasco F, and Sabatini S
- Subjects
- Anti-Bacterial Agents chemical synthesis, Anti-Bacterial Agents chemistry, Bacterial Proteins metabolism, Microbial Sensitivity Tests, Molecular Structure, Multidrug Resistance-Associated Proteins metabolism, Quinolines chemical synthesis, Quinolines chemistry, Staphylococcus aureus metabolism, Structure-Activity Relationship, Anti-Bacterial Agents pharmacology, Bacterial Proteins antagonists & inhibitors, Multidrug Resistance-Associated Proteins antagonists & inhibitors, Quinolines pharmacology, Staphylococcus aureus drug effects
- Abstract
NorA is the most studied efflux pump of Staphylococcus aureus and is responsible for high level resistance towards fluoroquinolone drugs. Although along the years many NorA efflux pump inhibitors (EPIs) have been reported, poor information is available about structure-activity relationship (SAR) around their nuclei and reliability of data supported by robust assays proving NorA inhibition. In this regard, we focussed efforts on the 2-phenylquinoline as a promising chemotype to develop potent NorA EPIs. Herein, we report SAR studies about the introduction of different aryl moieties on the quinoline C-2 position. The new derivative 37a showed an improved EPI activity (16-fold) with respect to the starting hit 1 . Moreover, compound 37a exhibited a high potential in time-kill curves when combined with ciprofloxacin against SA-1199B ( norA+) . Also, 37a exhibited poor non-specific effect on bacterial membrane polarisation and showed an improvement in terms of "selectivity index" in comparison to 1 .
- Published
- 2020
- Full Text
- View/download PDF
14. Structural Modifications of the Quinolin-4-yloxy Core to Obtain New Staphylococcus aureus NorA Inhibitors.
- Author
-
Cannalire R, Mangiaterra G, Felicetti T, Astolfi A, Cedraro N, Massari S, Manfroni G, Tabarrini O, Vaiasicca S, Barreca ML, Cecchetti V, Biavasco F, and Sabatini S
- Subjects
- A549 Cells, Anti-Bacterial Agents chemical synthesis, Humans, Quinolines chemical synthesis, Staphylococcus aureus metabolism, Structure-Activity Relationship, THP-1 Cells, Anti-Bacterial Agents pharmacology, Bacterial Proteins antagonists & inhibitors, Drug Resistance, Multiple, Bacterial, Multidrug Resistance-Associated Proteins antagonists & inhibitors, Quinolines pharmacology, Staphylococcus aureus drug effects
- Abstract
Tackling antimicrobial resistance (AMR) represents a social responsibility aimed at renewing the antimicrobial armamentarium and identifying novel therapeutical approaches. Among the possible strategies, efflux pumps inhibition offers the advantage to contrast the resistance against all drugs which can be extruded. Efflux pump inhibitors (EPIs) are molecules devoid of any antimicrobial activity, but synergizing with pumps-substrate antibiotics. Herein, we performed an in silico scaffold hopping approach starting from quinolin-4-yloxy-based Staphylococcus aureus NorA EPIs by using previously built pharmacophore models for NorA inhibition activity. Four scaffolds were identified, synthesized, and modified with appropriate substituents to obtain new compounds, that were evaluated for their ability to inhibit NorA and synergize with the fluoroquinolone ciprofloxacin against resistant S. aureus strains. The two quinoline-4-carboxamide derivatives 3a and 3b showed the best results being synergic (4-fold MIC reduction) with ciprofloxacin at concentrations as low as 3.13 and 1.56 µg/mL, respectively, which were nontoxic for human THP-1 and A549 cells. The NorA inhibition was confirmed by SA-1199B ethidium bromide efflux and checkerboard assays against the isogenic pair SA-K2378 ( norA ++)/SA-K1902 ( norA -). These in vitro results indicate the two compounds as valuable structures for designing novel S. aureus NorA inhibitors to be used in association with fluoroquinolones.
- Published
- 2020
- Full Text
- View/download PDF
15. Role of Tobramycin in the Induction and Maintenance of Viable but Non-Culturable Pseudomonas aeruginosa in an In Vitro Biofilm Model.
- Author
-
Mangiaterra G, Cedraro N, Vaiasicca S, Citterio B, Galeazzi R, Laudadio E, Mobbili G, Minnelli C, Bizzaro D, and Biavasco F
- Abstract
The recurrence of Pseudomonas aeruginosa (PA) biofilm infections is a major issue in cystic fibrosis (CF) patients. A pivotal role is played by the presence of antibiotic-unresponsive persisters and/or viable but non-culturable (VBNC) forms, whose development might be favored by subinhibitory antibiotic concentrations. The involvement of tobramycin and ciprofloxacin, widely used to treat CF PA lung infections, in the abundance of VBNC cells was investigated in PA biofilms models. In vitro biofilms of the laboratory strain PAO1-N and the clinical strain C24 were developed and starved by subculture for 170 days in a non-nutrient (NN) broth, unsupplemented or supplemented with one-quarter minimal inhibitory concentration (MIC) of tobramycin or ciprofloxacin. VBNC cells abundance, estimated as the difference between total live (detected by qPCR and flow cytometry) and colony forming unit (CFU) counts, showed a strain- and drug-specific pattern. A greater and earlier abundance of VBNC PAO1-N cells was detected in all conditions. Exposure of the C24 strain to NN and NN + ciprofloxacin induced only a transient VBNC subpopulation, which was more abundant and stable until the end of the experiment in tobramycin-exposed biofilms. The same response to tobramycin was observed in the PAO1-N strain. These findings suggest that low tobramycin concentrations might contribute to PA infection recurrence by favoring the development of VBNC forms.
- Published
- 2020
- Full Text
- View/download PDF
16. Plasmid Replicon Typing of Antibiotic-Resistant Escherichia coli From Clams and Marine Sediments.
- Author
-
Citterio B, Andreoni F, Simoni S, Carloni E, Magnani M, Mangiaterra G, Cedraro N, Biavasco F, and Vignaroli C
- Abstract
Unlike human isolates, environmental Escherichia coli isolates have not been thoroughly investigated for the diversity and transferability of antibiotic-resistant plasmids. In this study, antibiotic-resistant strains from marine sediment ( n = 50) and clams ( n = 53) were analyzed (i) for their plasmid content using a PCR-based plasmid replicon typing (PBRT) kit and (ii) for the transferability of plasmid-associated antibiotic resistance (AR) traits by mating experiments. Fifteen of the thirty replicons targeted by the PBRT kit were detected in the isolates; 8/15 were identified in both sediment and clam isolates, although at different frequencies. The most frequent replicons in sediment (74%) and in clam strains (66%) alike, were FIA, FIB, or FII, which are associated with the IncF group, followed by the I1α replicon, which was more frequent in clam (24.5%) than in sediment (10%) strains. More than 50% of the strains contained multiple replicons; although 15 were untypable, S1-PFGE analysis demonstrated that 14/15 carried no plasmids. All cryptic strains were successfully typed and were positive for IncF or IncI replicons. Antibiotic-resistant strains accounted for 63% of all isolates and were significantly ( p < 0.05) more frequent in phylogroup A. Most (35%) multidrug-resistant (MDR) strains belonged to phylogroup A, too. Although 25/26 MDR strains were positive for IncF plasmids (the exception being a clam strain), the FII-FIB rep combination was predominant (63%) among the sediment isolates, whereas most clam isolates (40%) carried the FII replicon alone. In mating experiments, selected MDR strains carrying FIB, FII, and I1α replicons, used as the donors, transferred multiple ARs together with the IncF or IncI plasmids at high frequency. Since IncI plasmids are common in E. coli and Salmonella enterica isolates from poultry, our findings suggest an animal origin to the E. coli clam strains carrying IncI plasmids. They also suggest a role for IncI plasmids in the spread of ARs among environmental Enterobacteriaceae and, through the food chain, to human isolates. In conclusion, the PBRT kit proved to be a useful tool to identify plasmids carrying antibiotic-resistant genes and to shed light on the factors underpinning their diffusion., (Copyright © 2020 Citterio, Andreoni, Simoni, Carloni, Magnani, Mangiaterra, Cedraro, Biavasco and Vignaroli.)
- Published
- 2020
- Full Text
- View/download PDF
17. Natural Alkaloid Berberine Activity against Pseudomonas aeruginosa MexXY-Mediated Aminoglycoside Resistance: In Silico and in Vitro Studies.
- Author
-
Laudadio E, Cedraro N, Mangiaterra G, Citterio B, Mobbili G, Minnelli C, Bizzaro D, Biavasco F, and Galeazzi R
- Subjects
- Berberine chemistry, Computer Simulation, Microbial Sensitivity Tests, Molecular Dynamics Simulation, Aminoglycosides pharmacology, Anti-Bacterial Agents pharmacology, Berberine pharmacology, Drug Resistance, Bacterial drug effects, Pseudomonas aeruginosa drug effects
- Abstract
The multidrug efflux system MexXY-OprM, inside the resistance-nodulation-division family, is a major determinant of aminoglycoside resistance in Pseudomonas aeruginosa . In the fight aimed to identify potential efflux pump inhibitors among natural compounds, the alkaloid berberine emerged as a putative inhibitor of MexXY-OprM. In this work, we elucidated its interaction with the extrusor protein MexY and assessed its synergistic activity with aminoglycosides. In particular, we built an in silico model for the MexY protein in its trimeric association using both AcrB ( E. coli ) and MexB ( P. aeruginosa ) as 3D templates. This model has been stabilized in the bacterial cytoplasmic membrane using a molecular dynamics approach and used for ensemble docking to obtain the binding site mapping. Then, through dynamic docking, we assessed its binding affinity and its synergism with aminoglycosides focusing on tobramycin, which is widely used in the treatment of pulmonary infections. In vitro assays validated the data obtained: the results showed a 2-fold increase of the inhibitory activity and 2-4 log increase of the killing activity of the association berberine-tobramycin compared to those of tobramycin alone against 13/28 tested P. aeruginosa clinical isolates. From hemolytic assays, we preliminarily assessed berberine's low toxicity.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.